Edwards Lifesciences Corp. unveiled a new option in its heart valve franchise on Tuesday. The Irvine-based valve maker’s Ascendra procedure uses an aortic heart valve replacement system that is less ...

An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.

Edwards Lifesciences (NYSE:EW) today announced 10-year results from the COMMENCE aortic trial supporting its proprietary ...

WASHINGTON (Reuters) - The minimally invasive aortic heart valve replacement system from Edwards Lifesciences Corp performed better than a rival product sold by Medtronic Inc in the first head-to-head ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

CHICAGO, Sept 21 (Reuters) - Nearly two-thirds of high-risk patients who received an Edwards Lifesciences Corp aortic heart valve through a less-invasive procedure were alive two years after the ...

April 23 (Reuters) - Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand for its artificial valves used in complex cardiac procedures, sending its shares ...

Edwards Lifesciences has claimed the FDA’s first approval of a transcatheter replacement implant for a leaky tricuspid heart valve, three months after garnering a green light in Europe. The Evoque, ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

The MITRIS RESILIA valve is made with innovative tissue technology RESILIA allowing the valve to potentially last longer than conventional bioprosthetic valves.* NYON, Switzerland--(BUSINESS ...